New Sancilio & Company, Inc. Scientific Board

Share Article

South Florida Pharmaceutical Company Creates Scientific Advisory Board

Sancilio & Company

Riviera Beach, Florida based Sancilio & Company Inc. (SCI) is announcing the creation of the Sancilio Scientific Advisory Board (SSAB). The board’s priority is to take the SCI’s philosophy of looking to nature for pharmaceutical advancements, and insuring the company’s research and development actions are based on sound scientific data, analyses, expertise and interpretations.

This new Scientific Advisory Board provides a vehicle for SCI to receive peer reviews and advice that make positive differences in developing good science into great medicine.

The advisory functions of SSAB include providing expert comment and consultation from board members of a clinical or scientific nature before the company begins work on a particular issue. The team will provide written and verbal advice on works-in progress, and assure accuracy and validity of those efforts. The board will serve to provide peer reviews of protocols, strategies, analytical methods and models.

The SSAB panel will provide advice and commentary, exchange ideas on the importance of pre-clinical, clinical or scientific study, and provide expert review of the company’s scientific publications.

Distinguished members of the Sancilio Scientific Advisory Board include:

  • Dr. Philip Calder Ph.D. of South Hampton University in Hampton, United Kingdom
  • Dr. Catherine Gura of Harvard/Boston Children’s Hospital in Boston, Massachusetts
  • Dr. Ian Lanza Ph.D. of The Mayo Clinic in Rochester, Minnesota
  • Dr. Mark Puder MD/Ph.D. of Harvard/Boston Children’s Hospital in Boston, Massachusetts
  • Dr. Roy Smith Ph.D. of Scripps Research Institute in Jupiter, Florida
  • Dr. Herbert Weissbach Ph.D. of Florida Atlantic University in Jupiter, Florida
  • Dr. Paul Ziajka MD from the Florida Lipid Institute of Orlando, Florida

For more information on Sancilio & Company, Inc. or the Sancilio Scientific Advisory Board, the company may be contacted at 561.847-2302. The company’s main office is located at 3874 Fiscal Court, Suite 100, Riviera Beach, Florida 33404-1785. Their website is available at

About Sancilio & Company
Sancilio & Company is a specialty pharmaceutical company engaged in the development, commercialization, and manufacture of branded prescription, over-the-counter (“OTC”) and generic prescription pharmaceutical products. We leverage our formulation expertise and proprietary Advanced Lipid Technology™ (“ALT”) platform to develop, collaboratively with contract services clients and on our own, products intended to address the unmet medical needs of patients in the therapeutic areas of lipid disorders, cardiovascular disease, liver disease, pancreas-related disease, metabolic diseases, and endocrine disorders, especially those that are a result of reversible imbalances of essential lipophilic substances that impact the structure and function of the body. We also have significant expertise related to soft gelatin encapsulation, which offers unique advantages as a high barrier dosage form. We have a diversified product portfolio of established branded pharmaceutical products and product candidates. Our current marketable pharmaceutical products are OTC and behind-the-counter lines of highly concentrated omega-3 essential fatty acids products designed to improve cardiovascular and metabolic health under the brand Ocean Blue®, and generic prescription drug products in the dental and women’s health markets. Their website may be viewed at

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Chad Harrell, Vice President, Commercial Operations
Visit website